Research & Development
We have 4 leading R & D groups, with a total of 250 employees, which focus on the development of innovative patent medicines and first-class generic drugs, respectively. Our main research scientists, on average, have more than 10 years of experience developing new drugs in multinational pharmaceutical companies. We use a market approach to select research and development objectives that have the potential for widespread acceptance in the market or are best in their class among similar products. In total, we have 46 drugs at different stages of development, including 12 innovative patented drugs.
In addition, we are working with leading research institutes, universities and hospitals to further expand access to patented products and to minimise costs and risks associated with early development. Our investments in research and development were significantly higher than the national average and accounted for 3 to 11% of sales since 2003.
We believe that the development and launch of proprietary products are important for our sustained growth and future success.
Laboratory testing (LTD)
Laboratory testing (LTD) consists of 3 business units. Complex services and solutions LTD in the field of chemistry and biology range from early screening to preclinical development and analysis of clinical samples. Using other established ZPHC enterprises in MedChem, synthesis and formulation, LTD offers customers good opportunities to speed up the process of their discovery and enable them to bring new, innovative medicines to patients.
Development and production API
ZPHC API is a subsidiary of ZPHC, which is an integrated platform with “through” small API / intermediary molecules for development and production from preclinical to commercial stages. We proudly support more than 100 customers in the field of science.
ZPHC provides end-to-end API services from research and development to the development of APIs in phases I, II, III and commercial sales. These services also includes preliminary research, analytical development, stability assessment and wording development, including CMC services. All these services are integrated to help our clients quickly and seamlessly move the NCC from the preclinical stage to the patients.
ZPHC offers a full range of chemistry services, which are headed by experts in the relevant fields: from synthetic chemistry to chiral branches, from small molecules to peptides / peptidomimetics, from nucleoside to fluorinated building blocks, from synthesis of milligrams to increasing kilograms of GLP, and from Reagent services to integrated management.
Clinical and normative services
ZPHC has extensive experience in advising on clinical trials and regulatory advice; our specialists can provide comprehensive support to help customers bring new drugs and devices to the market faster.